Anticancer drug utilizing Trans-splicing Ribozyme technology Second Fast Track Designation following brain cancer approval SEONGNAM, South Korea, Feb. 18, 2025 /PRNewswire/ — Rznomics announced on the 14th that its anticancer drug, RZ-001, has received Fast Track Designation from the U.S….
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.